{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:46:27Z","timestamp":1790405187264,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.addr.2024.115193","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T23:54:56Z","timestamp":1706918096000},"page":"115193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings"],"prefix":"10.1016","volume":"207","author":[{"given":"Michael Z.","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Gibiansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Samineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Dere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben-Quan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2024.115193_b0005","unstructured":"Genentech Inc. POLIVY\u00ae [polatuzumab vedotin-piiq] Prescribing Information. Available at: https:\/\/www.gene.com\/download\/pdf\/polivy_prescribing.pdf (2023). Accessed May 2023."},{"key":"10.1016\/j.addr.2024.115193_b0010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2024.115193_b0015","first-page":"2721","article-title":"Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma","volume":"114","author":"Dornan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.addr.2024.115193_b0020","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2024.115193_b0025","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bph.13697","article-title":"Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells","volume":"174","author":"Fuh","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.addr.2024.115193_b0030","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2007-01-066704","article-title":"Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma","volume":"110","author":"Polson","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.addr.2024.115193_b0035","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2024.115193_b0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2024.115193_b0045","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure-what to do?, Hematology","volume":"2016","author":"Coiffier","year":"2016","journal-title":"American Society of Hematology. Education Program"},{"key":"10.1016\/j.addr.2024.115193_b0050","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.addr.2024.115193_b0055","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2024.115193_b0060","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2024.115193_b0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.addr.2024.115193_b0070","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbmt.2014.06.036","article-title":"Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation","volume":"20","author":"Hamadani","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.addr.2024.115193_b0075","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.23524","article-title":"Outcomes of patients with relapsed\/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era","volume":"88","author":"Nagle","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.addr.2024.115193_b0080","first-page":"CD013365","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma","volume":"9","author":"Ernst","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.addr.2024.115193_b0085","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2024.115193_b0090","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/psp4.12482","article-title":"Integrated two-analyte population pharmacokinetic model of polatuzumab vedotin in patients with non-Hodgkin lymphoma","volume":"9","author":"Lu","year":"2020","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.addr.2024.115193_b0095","article-title":"Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed\/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study","author":"Kinoshita","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.addr.2024.115193_b0100","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2024.115193_b0105","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.addr.2024.115193_b0110","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/blood.V128.22.622.622","article-title":"Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib\/II Study","volume":"128","author":"Phillips","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.addr.2024.115193_b0115","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","article-title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b\u20132 study","volume":"20","author":"Tilly","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2024.115193_b0120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/hon.2438_144","article-title":"Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed\/refractory FL or DLBCl: Updated results of a phase 1b\/2 study","volume":"35","author":"Matasar","year":"2017","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.addr.2024.115193_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10061323","article-title":"Preclinical characterization of the distribution, catabolism, and elimination of a polatuzumab vedotin-piiq (POLIVY\u00ae) antibody-drug conjugate in sprague dawley rats","volume":"10","author":"Yip","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2024.115193_b0130","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11095-020-02933-6","article-title":"Application of a two-analyte integrated population pharmacokinetic model to evaluate the impact of intrinsic and extrinsic factors on the pharmacokinetics of polatuzumab vedotin in patients with non-Hodgkin lymphoma","volume":"37","author":"Lu","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2024.115193_b0135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00280-020-04119-8","article-title":"Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"86","author":"Shi","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.addr.2024.115193_b0140","first-page":"S120","article-title":"Physiologically based pharmacokinetic model-Informed drug development for polatuzumab vedotin: Label for drug-drug interactions without dedicated clinical trials","volume":"60","author":"Samineni","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2024.115193_b0145","unstructured":"European Medicines Agency. Assessment report: Polivy (polatuzumab vedotin). Available at: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/polivy-epar-public-assessment-report_en.pdf (2019). Accessed January 2023."},{"key":"10.1016\/j.addr.2024.115193_b0150","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1080\/10428194.2020.1795154","article-title":"Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"61","author":"Lu","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.addr.2024.115193_b0155","article-title":"Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE)","volume":"10","author":"Chang","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2024.115193_b0160","first-page":"1195","article-title":"Tissue distribution, metabolism, and excretion of the antibody-drug conjugate Herceptin-monomethyl auristatin E in rats","volume":"65","author":"Pastuskovas","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2024.115193_b0165","unstructured":"US Food and Drug Administration. Clinical Pharmacology and Biopharmaceutics Review: Brentuximab Vedotin. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/125388Orig1s000ClinPharmR.pdf (2011). Accessed January 2023."},{"key":"10.1016\/j.addr.2024.115193_b0170","doi-asserted-by":"crossref","first-page":"997","DOI":"10.4155\/bio.13.38","article-title":"Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper","volume":"5","author":"Gorovits","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.addr.2024.115193_b0175","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4155\/bio.12.299","article-title":"Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics","volume":"5","author":"Kaur","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.addr.2024.115193_b0180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-136361","article-title":"Polatuzumab vedotin plus venetoclax with rituximab in relapsed\/refractory diffuse large B-cell lymphoma: Primary efficacy analysis of a Phase Ib\/II Study","volume":"136","author":"Gritti","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.addr.2024.115193_b0185","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1200\/JCO.2021.39.15_suppl.7512","article-title":"Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b\/2 trial","volume":"39","author":"Diefenbach","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2024.115193_b0190","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/psp4.12137","article-title":"Integrated Two-Analyte Population Pharmacokinetic Model for Antibody-Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling","volume":"5","author":"Lu","year":"2016","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.addr.2024.115193_b0195","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/jjco\/hyaa169","article-title":"Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed\/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study","volume":"51","author":"Kinoshita","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.addr.2024.115193_b0200","doi-asserted-by":"crossref","first-page":"1699768","DOI":"10.1080\/19420862.2019.1699768","article-title":"Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies","volume":"12","author":"Li","year":"2020","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2024.115193_b0205","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/jcph.116","article-title":"CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies","volume":"53","author":"Han","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2024.115193_b0210","first-page":"98","article-title":"Monomethyl auristatin E, a potent cytotoxic payload for development of antibody-drug conjugates against breast cancer","volume":"5","author":"Abdollahpour-Alitappeh","year":"2017","journal-title":"Novel Biomed"},{"key":"10.1016\/j.addr.2024.115193_b0215","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1111\/bph.14784","article-title":"Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin","volume":"176","author":"Li","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.addr.2024.115193_b0220","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/psp4.12192","article-title":"Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens","volume":"6","author":"Lu","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.addr.2024.115193_b0225","unstructured":"European Medicines Agency. ICH Topic E 14. The Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-14-clinical-evaluation-qt\/qts-interval-prolongation-proarrhythmic-potential-non-antiarrhythmic-drugs-step-5_en.pdf (2005). Accessed January 2023."},{"key":"10.1016\/j.addr.2024.115193_b0230","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40268-020-00321-4","article-title":"Comparability Considerations and Challenges for Expedited Development Programs for Biological Products","volume":"20","author":"Schrieber","year":"2020","journal-title":"Drugs R D"},{"key":"10.1016\/j.addr.2024.115193_b0235","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.yrtph.2015.01.014","article-title":"An FDA oncology analysis of antibody-drug conjugates","volume":"71","author":"Saber","year":"2015","journal-title":"Regul. Toxicol. Pharm."},{"key":"10.1016\/j.addr.2024.115193_b0240","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/leu.2015.48","article-title":"Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes","volume":"29","author":"Pfeifer","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.addr.2024.115193_b0245","unstructured":"European Medicines Agency. POLIVY\u00ae Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/polivy-epar-product-information_en.pdf (2022). Accessed August 2023."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X24000152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X24000152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:39:51Z","timestamp":1759210791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X24000152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":49,"alternative-id":["S0169409X24000152"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2024.115193","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2024.115193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115193"}}